Back to Search

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients


  • Protocol Number: 202008197
  • Principal Investigator: Oh, Stephen
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions